Peripheral artery disease (PAD) is common, with over 10M confirmed diagnoses in the US alone. It's also frequently missed in the early stage (particularly among people with diabetes, kidney disease, and other cardiovascular risk factors), making it especially deadly. Patients often are unaware of the condition until after they experience their first heart attack, stroke, or amputation, and 5-year PAD mortality exceeds 30%. While diagnostic tests like the ankle-brachial index exist, they are difficult to deploy at scale, suffering from lengthy workflows and large amounts of inter-observer variability. Thus, population-level PAD screening has remained impractical until today for all stakeholders, despite projections that over one-third of the United States will die from cardiovascular disease in their lifetimes. 

ImageAiD solves this problem with a handheld ultrasound platform that uses AI to help clinicians identify PAD and assess a patient’s risk of heart attack, stroke, amputation, and death from just seconds of noninvasive arterial data. The technology transforms a lengthy, operator dependent workflow into a rapid, objective assessment that can be performed across a wide range of care settings. By combining disease detection and risk stratification in a single exam, ImageAiD helps clinicians understand not only which patients have PAD, but which patients may require the most urgent intervention. This creates a faster, simpler, and more scalable approach to vascular screening that expands access to earlier care, improves clinical efficiency, and helps prevent costly, life changing complications.

Peripheral artery disease (PAD) is common, with over 10M confirmed diagnoses in the US alone. It's also frequently missed in the early stage (particularly among people with diabetes, kidney disease, and other cardiovascular risk factors), making it especially deadly. Patients often are unaware of the condition until after they experience their first heart attack, stroke, or amputation, and 5-year PAD mortality exceeds 30%. While diagnostic tests like the ankle-brachial index exist, they are difficult to deploy at scale, suffering from lengthy workflows and large amounts of inter-observer variability. Thus, population-level PAD screening has remained impractical until today for all stakeholders, despite projections that over one-third of the United States will die from cardiovascular disease in their lifetimes. 

ImageAiD solves this problem with a handheld ultrasound platform that uses AI to help clinicians identify PAD and assess a patient’s risk of heart attack, stroke, amputation, and death from just seconds of noninvasive arterial data. The technology transforms a lengthy, operator dependent workflow into a rapid, objective assessment that can be performed across a wide range of care settings. By combining disease detection and risk stratification in a single exam, ImageAiD helps clinicians understand not only which patients have PAD, but which patients may require the most urgent intervention. This creates a faster, simpler, and more scalable approach to vascular screening that expands access to earlier care, improves clinical efficiency, and helps prevent costly, life changing complications.

"This accelerator takes an elite cohort of health care companies and gives them access to institutions who lead the world in innovation and patient care. "

Josh Hanson
Founder and Chief Executive Officer of ImageAiD